Alzamend Neuro Inc ALZN
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-15 |
| Shares Out. | 4,790,000 |
| Website | alzamend.com/ ↗ |
| Phone | 13026365400 |
| Employees | 6 |
| Net Income | -$2.9M |
| Total Assets | $2.1M |
| Total Liabilities | $1.3M |
| Equity | $733,211 |
About Alzamend Neuro Inc
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Alzamend Neuro Inc is a publicly traded company under the ticker symbol ALZN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)